A$279M Laboratory Deal: TPG’s Investment in Vietnam

How TPG Capital Asia’s acquisition of 39 diagnostic laboratories demonstrated the investment potential of Southeast Asian healthcare infrastructure—and what it could mean for Vietnam’s growing pathology industry.

In August 2018, international private equity firm TPG Capital Asia completed a transaction that demonstrated the investment potential of Southeast Asia’s diagnostic laboratory industry.

The deal involved the acquisition of Healthscope’s Asian pathology and laboratory operations for A$279 million, equivalent to approximately US$200 million at the time.

The acquired business comprised 39 laboratories across Singapore, Malaysia and Vietnam, operating under two established brands: Quest Laboratories and Gribbles Pathology.

For Vietnam’s healthcare investment market, one detail deserves particular attention.

Vietnamese laboratory operations were already part of a major cross-border diagnostic acquisition nearly a decade ago.

The transaction showed that Southeast Asian laboratory businesses could attract substantial institutional capital, even when their operations extended across healthcare markets with different economic conditions, regulatory systems and levels of medical infrastructure development.

The A$279 Million Transaction: What Did TPG Acquire?

On July 30, 2018, Healthscope announced an agreement to sell its Asian pathology operations to entities controlled by funds managed by TPG Capital Asia. The acquisition was completed on August 17, 2018.

The transaction included an established regional laboratory network with recurring healthcare relationships, operational infrastructure and recognised diagnostic brands.

Source: Healthscope’s July 2018 transaction announcement, FY2018 financial disclosures and contemporary financial reporting.

The acquired laboratories generated approximately A$18.2 million in earnings before interest, taxes, depreciation and amortisation (EBITDA) during the 2017 financial year.

By FY2018, reported segment operating EBITDA had increased to A$20.3 million. Healthscope subsequently reported a transaction valuation multiple of approximately 13.7 times FY2018 EBITDA.

These figures are significant because they provide a documented financial reference for how an established, multi-country diagnostic laboratory network was valued.

They do not, however, indicate how an individual Vietnamese laboratory would be valued. The transaction price reflected the combined operations of a regional business, rather than the financial performance of any single country or laboratory specialty.

Why Was Vietnam Included in a Regional Laboratory Acquisition?

At the time of the transaction, Healthscope operated Quest Laboratories in Singapore and Vietnam, while Gribbles Pathology served Malaysia and surrounding markets.

Healthscope described its Vietnamese presence as relatively small. Nevertheless, those operations formed part of the larger acquisition.

This distinction matters.

Vietnam was not necessarily the principal driver of the transaction’s valuation. However, it was already included in a regional diagnostic laboratory platform sufficiently established to attract international private equity investment.

For investors studying Vietnam’s diagnostic industry, the acquisition illustrates how local laboratory businesses can potentially contribute to a broader regional investment strategy.

A laboratory operating independently in Vietnam may have a limited geographic reach. When integrated into a larger network, it can potentially benefit from technical expertise, established operating procedures, procurement arrangements and access to specialist diagnostic capabilities.

The strategic value may therefore extend beyond the revenue generated by individual laboratory locations.

It may also depend on how effectively those locations can participate in a wider diagnostic service network.

Why Private Equity Investors Are Interested in Diagnostic Laboratories

Diagnostic laboratories occupy a distinctive position within healthcare infrastructure.

Unlike many healthcare businesses that depend primarily on individual patient appointments, laboratories can develop ongoing institutional relationships with hospitals, clinics, specialist physicians and other medical service providers.

These relationships can support recurring testing volumes, although demand, pricing and profitability remain sensitive to clinical activity, competition and reimbursement arrangements.

Several characteristics make established laboratory businesses potentially attractive to private equity investors.

1. Recurring relationships with healthcare providers

Hospitals and clinics routinely depend on laboratory testing for diagnosis, treatment planning and disease monitoring.

Once a laboratory establishes reliable service quality, turnaround times and reporting processes, it may develop long-term referral relationships with healthcare providers.

These relationships are not guaranteed revenue contracts. Nevertheless, a diversified referral network can create a more predictable operating foundation than one-time consumer transactions.

2. Opportunities for operational consolidation

Laboratories require investments in equipment, quality assurance, information systems, logistics and qualified personnel.

When several laboratories belong to the same group, certain functions can potentially be consolidated.

Centralised procurement may improve purchasing efficiency. Shared information systems may support reporting and operational oversight. Selected specialised testing services may be concentrated in designated reference laboratories.

However, consolidation must be balanced against specimen stability, transport time, regulatory requirements and clinical turnaround expectations.

3. Potential economies of scale

Laboratory operating costs include both fixed and variable components.

Equipment, facilities, technology systems and certain personnel expenses may remain relatively stable across different testing volumes.

Where available capacity permits, increasing sample volumes can potentially improve equipment utilisation and spread fixed expenses across more tests.

But this is not automatic.

Additional testing may require further investment in staffing, instruments, accreditation, transport and quality controls.

The most attractive laboratory networks are therefore not necessarily the largest. They are those capable of expanding volume while maintaining clinical quality and sustainable margins.

Why Acquisitions Can Be More Attractive Than Building Laboratories From Scratch

Creating a new diagnostic laboratory involves considerably more than purchasing analytical equipment.

Investors must establish clinical relationships, recruit qualified professionals, obtain the appropriate regulatory approvals and develop reliable operating procedures.

They must also build confidence among the physicians and healthcare institutions responsible for requesting diagnostic tests.

This process can take years.

Acquiring an existing laboratory can provide access to infrastructure and established customers more quickly than developing an equivalent business organically.

In addition, acquisitions may bring laboratory management teams, trained employees, historical testing data, operational systems and relationships with medical specialists.

For a private equity investor pursuing regional expansion, these capabilities can be valuable.

Yet acquisitions also introduce integration risks.

Different laboratories may use incompatible information systems, inconsistent reporting standards or varying quality management procedures.

Successfully combining laboratories requires more than financial consolidation. It requires the standardisation of operating practices without compromising diagnostic reliability.

The 2018 Healthscope transaction illustrates the scale at which investors were prepared to pursue this strategy across Southeast Asia.

From a Laboratory Acquisition to a Regional Growth Platform

The significance of the Healthscope deal extended beyond the initial acquisition.

Following the transaction, the acquired operations became part of the foundation for Pathology Asia Holdings, a regional diagnostic laboratory platform.

TPG subsequently pursued expansion opportunities, including the acquisition of Singapore-based Innovative Diagnostics.

By 2021, reports indicated that TPG was considering a potential public listing of Pathology Asia Holdings.

Contemporary reporting cited an estimated valuation of approximately US$2 billion for the expanded business, although this was a reported indicative valuation rather than a confirmed completed transaction at that value.

This development demonstrated an important feature of the private equity investment model.

An initial acquisition can serve as the foundation for further expansion through additional laboratory acquisitions, operational integration and geographic development.

The investment thesis is not simply to own more laboratories.

It is to create a larger, potentially more efficient diagnostic business with a broader customer base and stronger technical capabilities.

Whether the strategy ultimately creates value depends on acquisition discipline, integration effectiveness, financial performance and the quality of diagnostic services.

Why This Matters for Vietnam’s Histopathology Industry

For Vietnam’s histopathology industry, the 2018 acquisition provides useful strategic context—but it must be interpreted carefully.

The Healthscope transaction involved a broad diagnostic laboratory network, not a standalone histopathology business.

Diagnostic laboratory operations can include clinical chemistry, haematology, microbiology and other testing services.

Histopathology, which focuses on the microscopic examination of tissue samples to diagnose disease, has a different operating structure.

Its performance depends heavily on access to qualified pathologists, specimen-processing expertise, diagnostic interpretation and rigorous quality assurance.

An automated laboratory may be able to process increasing test volumes through additional equipment and workflow optimisation.

A histopathology laboratory faces a more specialised constraint: professional diagnostic capacity.

Expanding tissue-processing infrastructure does not automatically increase the availability of experienced pathologists.

For investors, this creates both a challenge and a potential opportunity.

Laboratory groups that successfully combine specialist medical expertise with reliable infrastructure, efficient workflows and referral networks may develop differentiated competitive advantages.

Digital pathology and telepathology could also support collaboration between laboratories and specialist physicians across locations, subject to appropriate validation, regulatory compliance and clinical oversight.

However, the investment case must ultimately be supported by actual diagnostic demand, quality performance, operating economics and sustainable access to medical specialists.

Can Vietnam’s Specialist Pathology Laboratories Attract Similar Investment?

The Healthscope transaction suggests that Southeast Asian diagnostic infrastructure can be institutionally investable.

It does not establish that Vietnamese histopathology laboratories will command comparable valuation multiples.

Several factors would influence the attractiveness of a specialist pathology business.

Clinical capability: The laboratory must demonstrate access to qualified pathologists, consistent diagnostic quality and reliable clinical reporting.

Referral network: Relationships with hospitals, oncology centres, clinics and medical specialists are important for generating sustainable case volumes.

Operating infrastructure: Tissue processing, staining, immunohistochemistry, information systems and quality management all influence service capacity.

Scalability: Investors must assess whether case volumes can increase without creating excessive dependence on a small number of specialists.

Financial performance: Revenue quality, EBITDA margins, capital expenditure, working capital requirements and customer concentration remain essential valuation considerations.

In particular, histopathology investors must distinguish between businesses that merely operate laboratory equipment and those that control a sustainable specialist diagnostic capability.

The latter may possess stronger competitive advantages, but those advantages require careful verification.

What the A$279 Million Deal Really Proves

The 2018 acquisition provides three important lessons for Vietnam’s diagnostic investment market.

First, Southeast Asian laboratory consolidation is not a new investment concept. International private equity capital had already entered the sector through a substantial cross-border acquisition.

Second, Vietnam was part of that investment footprint. Its diagnostic laboratory operations were included alongside established businesses in Singapore and Malaysia.

Third, regional laboratory platforms can potentially create value beyond individual laboratory locations, particularly through clinical relationships, specialist services, shared infrastructure and operational scale.

Nevertheless, these lessons should not be confused with a valuation forecast for Vietnam’s pathology businesses.

The A$279 million acquisition was a historical transaction involving an established regional network. Its financial characteristics cannot be transferred directly to smaller, specialist laboratories operating in a different market environment.

Conclusion: An Established Precedent, Not a Future Guarantee

The acquisition of Healthscope’s Asian laboratory operations by TPG Capital Asia remains an important reference point for investors evaluating Southeast Asian diagnostics.

It demonstrated that an established network of laboratories spanning Singapore, Malaysia and Vietnam could attract an investment worth hundreds of millions of Australian dollars.

For Vietnam, the transaction is particularly relevant because it confirms that local diagnostic operations were already included in a major international healthcare acquisition in 2018.

The next question is whether Vietnamese specialist pathology businesses can develop the clinical capabilities, operating standards, referral networks and financial scale required to attract comparable strategic interest.

The opportunity is not simply to establish more laboratories.

It is to build specialist diagnostic businesses that are clinically trusted, operationally scalable and financially sustainable.

That is where the long-term investment potential of Vietnam’s pathology industry may lie.

References and further reading

1. Healthscope — Announcement of Asian Pathology Sale, July 30, 2018. Original transaction announcement, including consideration, laboratory count and EBITDA.

2. The Business Times — TPG Completes A$279m Acquisition, August 17, 2018. Confirmation of transaction completion.

3. Healthscope — Annual Report 2018. Historical financial performance and operating footprint.

4. Allens — Legal Advisory on Healthscope’s Asian Pathology Sale. Transaction structure and regional scope.

5. The Straits Times — TPG Considers Pathology Asia IPO, 2021. Subsequent regional expansion and reported listing considerations.